Lung cancer statistics, 2023.
Level 4 - case-series / case-control
Descriptive population-based registry and surveillance study.
PubMed 38279776 · doi:10.1002/cncr.35128
What was done
The authors analyzed lung cancer incidence, stage at diagnosis, 2-year relative survival, and mortality trends using US population-based surveillance registry data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries.
What was found
Over the past 5 years, annual mortality reductions outpaced incidence declines for men (5.0% vs. 2.6%) and women (4.3% vs. 1.1%), accompanied by an annual gain in 2-year relative survival of 1.4%. From 2013 to 2019, distant-stage disease incidence fell by 4.6% annually while localized-stage disease rose by 3.6% annually, increasing faster in states with high screening prevalence (3%-5% per year) than low screening prevalence (1%-2% per year). Native Americans exhibited the highest incidence and slowest improvement (<1% annual decline in men, flat in women), and mortality rates in Mississippi and Kentucky were two to three times higher than in most western states.
Why it matters
The findings demonstrate measurable population-level progress in lung cancer survival and early-stage detection, while defining critical racial and regional disparities where prevention and screening interventions remain underutilized.
Limits
The abstract provides aggregate registry trends rather than individual-level data, does not report total sample size (n), and does not measure individual treatment regimens, histology specifics, or adherence.
Cited by
- supports Lung cancer is the leading cause of cancer death globally and in the United States for both men and women, and 85% of lung cancers occur in current or former smokers.